Q2 2026 Coloplast A/S Earnings Call Transcript
Key Points
- Coloplast AS (CLPBF) reported strong organic growth in several segments, including Ostomy Care and Continence Care, with notable contributions from the US market.
- The company's SenSura Mio and Luja catheter portfolio are driving significant growth, showcasing successful product innovation.
- Coloplast AS (CLPBF) has renewed national group purchasing agreements with major US GPOs, Vizient and Premier, indicating strong market positioning.
- The acquisition of Uromedica is progressing well, enhancing the company's Men's Health business.
- Operating cash flow increased significantly, with a 16% rise in free cash flow, indicating strong financial health.
- The Wound & Tissue repair segment underperformed, with organic growth at minus 2% in Q2, impacting overall financial performance.
- China's market remains challenging due to weak consumer sentiment and competitive pressures, leading to expected sales decline.
- The gross margin decreased to 67% from 68% last year, affected by currency fluctuations and ramp-up costs in new manufacturing sites.
- Inflationary pressures on raw materials are anticipated to impact costs in the latter part of the year.
- The outpatient business in the US is facing significant sales decline due to reimbursement changes, affecting the overall growth outlook.
Ladies and gentlemen, welcome to the Coloplast interim financial statement for H1 2025/26 conference call. I'm Lorenzo, the Chorus Call operator.
(Operator Instructions) The conference is being recorded. (Operator Instructions)
The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Anders Lonning-Skovgaard, Executive Vice President and CFO. Please go ahead, sir.
/- -
Anders Lonning-SkovgaardExecutive Our Q2 '25/'26 conference call. I am Anders Lonning-Skovgaard, CFO of Coloplast, and I'm very happy to introduce our new President and CEO, Gavin Wood who joined the company on May 1. Please turn to slide number 3.
/- -
Thank you, Anders, and good morning,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
